DRC Ebola Response: Need To “Find A Balance” Between Protecting Patients, Building Trust 14/03/2019 David Branigan World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus told reporters today that WHO is “working to find a balance between protecting patients and staff from attacks by armed groups and building community trust and ownership” in managing the response to the deadly Ebola epidemic in the Democratic Republic of Congo. Image Credits: Gabriele François Casini/MSF. Continue reading -> UCLA Students Protest University Patent Claim On Prostate Cancer Treatment 13/03/2019 Divya Schlesinger Students at the University of California, Los Angeles (UCLA) renewed their protests today against a patent claim in an Indian High Court over a leading prostate cancer treatment, saying the claim, if successful, could make the drug unaffordable to millions of people in the developing world. Image Credits: Neda Ashtari. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> New WHO Global Influenza Strategy Aims to Strengthen Country Response 11/03/2019 David Branigan The World Health Organization today launched a new influenza strategy that takes a more holistic approach to protecting people worldwide from deadly flu threats. The Global Influenza Strategy 2019-2030 aims to address both seasonal prevention and control of influenza, as well as preparedness for future pandemics, while building the capacity of countries to respond to […] Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
UCLA Students Protest University Patent Claim On Prostate Cancer Treatment 13/03/2019 Divya Schlesinger Students at the University of California, Los Angeles (UCLA) renewed their protests today against a patent claim in an Indian High Court over a leading prostate cancer treatment, saying the claim, if successful, could make the drug unaffordable to millions of people in the developing world. Image Credits: Neda Ashtari. Continue reading -> WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> New WHO Global Influenza Strategy Aims to Strengthen Country Response 11/03/2019 David Branigan The World Health Organization today launched a new influenza strategy that takes a more holistic approach to protecting people worldwide from deadly flu threats. The Global Influenza Strategy 2019-2030 aims to address both seasonal prevention and control of influenza, as well as preparedness for future pandemics, while building the capacity of countries to respond to […] Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHA Resolution For Transparent Drug Pricing: Italy Speaks Out 12/03/2019 Elaine Ruth Fletcher Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading -> New WHO Global Influenza Strategy Aims to Strengthen Country Response 11/03/2019 David Branigan The World Health Organization today launched a new influenza strategy that takes a more holistic approach to protecting people worldwide from deadly flu threats. The Global Influenza Strategy 2019-2030 aims to address both seasonal prevention and control of influenza, as well as preparedness for future pandemics, while building the capacity of countries to respond to […] Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New WHO Global Influenza Strategy Aims to Strengthen Country Response 11/03/2019 David Branigan The World Health Organization today launched a new influenza strategy that takes a more holistic approach to protecting people worldwide from deadly flu threats. The Global Influenza Strategy 2019-2030 aims to address both seasonal prevention and control of influenza, as well as preparedness for future pandemics, while building the capacity of countries to respond to […] Continue reading -> CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Accelerator Network On Antibacterial Research Expands 26/02/2019 William New A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts